KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Cash from Investing Activities (2016 - 2025)

NovoCure's Cash from Investing Activities history spans 12 years, with the latest figure at $336.3 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 1614.23% year-over-year to $336.3 million; the TTM value through Dec 2025 reached $437.3 million, up 411.8%, while the annual FY2025 figure was $437.3 million, 411.8% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was $336.3 million at NovoCure, up from $71.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $336.3 million in Q4 2025 and bottomed at -$499.1 million in Q4 2021.
  • The 5-year median for Cash from Investing Activities is $13.7 million (2023), against an average of $9.8 million.
  • The largest annual shift saw Cash from Investing Activities soared 6049.47% in 2022 before it plummeted 2594.39% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$499.1 million in 2021, then surged by 74.34% to -$128.1 million in 2022, then skyrocketed by 176.92% to $98.5 million in 2023, then crashed by 122.55% to -$22.2 million in 2024, then soared by 1614.23% to $336.3 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Cash from Investing Activities are $336.3 million (Q4 2025), $71.4 million (Q3 2025), and $36.0 million (Q2 2025).